In the US, around 10% to 15% of all lung cancer patients test positive for the EGFR mutation, and Asian patients have a higher EGFR mutation frequency (51.4% overall) in tumors.[36,37] Researchers discovered that drugs that inhibit the EGFR pathway may be helpful to prevent or restrain the growth of lung cancer cells with EGFR mutation. Here, EGFR is linked to lung carcinoma.